ERBB2 and breast cancer: The authors demonstrated that breast cancer cell lines over expressing HER2, release exosomes expressing a full-length HER2 molecule that is able to bind, both in vitro and in vivo, to the HER2 antibody, Trastuzumab, resulting in a reduced amount of antibodies available for the antibody-dependent cytotoxicity [125].